# A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

> **NCT05593094** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 210 (estimated)

## Conditions studied

- Advanced Solid Tumors
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** ZN-A-1041
- **DRUG:** ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b
- **DRUG:** ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
- **DRUG:** ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b
- **DRUG:** ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c
- **DRUG:** ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c
- **DRUG:** ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c

## Key facts

- **NCT ID:** NCT05593094
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-03
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593094, "A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05593094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*